Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's in stroke compound supply deal with Sygnis

Dr Reddy's signs an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient for stroke and other neurodegenrative disorders

Indian pharmaceutical company Dr Reddy's Laboratories has signed an exclusive 10-year agreement with Germany-based Sygnis Pharma for the supply of an ingredient used in the treatment of stroke and other neurodegenrative disorders.

The active ingredient is biological molecule AX200, which is being developed by Sygnis. The company successfully completed phase IIa clinical trials of the compound in September 2007, which demonstrated safety and efficacy in patients with acute stroke.

Sygnis plans to begin phase IIb trial in H2 2008. The study will be an efficacy trial in acute stroke. AX200 is the most advanced product in Sygnis' portfolio.

Cartikeya Reddy, head of biologics, at Dr Reddy's, said: "Our strategic decision to exclusively produce a biological molecule for a partner is a first in the history of Dr Reddy's and fits very well within our custom pharmaceutical services' business model. We are very optimistic that AX200 will continue to show real potential in the treatment of acute stroke with the potential to be used in the treatment of other degenerative neurological diseases."

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics